UroGen Pharma
URGN
21 hedge funds and large institutions have $85.2M invested in UroGen Pharma in 2017 Q2 according to their latest regulatory filings, with 21 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
39.41% more ownership
Funds ownership: 0% → 39.41% (+39%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
ProQuest Associates IV
Naples,
Florida
|
+$25.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.4M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$13.1M |
| 4 |
HCM
Highline Capital Management
New York
|
+$7.38M |
| 5 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$6.12M |
Top Sellers
URGN Hedge Fund Activity: Q2 2017 in Review
21 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q2 2017, worth a combined $85.2M.
Buyers outnumbered sellers: 21 funds opened new URGN positions and 0 closed out — a net gain of 21 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was ProQuest Associates IV, opening a new position worth an estimated $25.2M.
- 21 institutional investors held UroGen Pharma (URGN) as of Q2 2017, up from 0 in Q1 2017.
- Funds reported $85.2M of UroGen Pharma stock for Q2 2017.
- 21 funds opened new UroGen Pharma positions in Q2 2017 and 0 closed out, a net change of +21 holders.
- The largest UroGen Pharma buyer in Q2 2017 was ProQuest Associates IV, an estimated $25.2M added.
Based on aggregated 13F filings for Q2 2017.